Harold Feldman , MD, MSCE
George S. Pepper Professor of Public Health and Preventive Medicine, Biostatistics, Epidemiology and Informatics
Public Health Interests
Current Public-Health Related Activities
Harold I. Feldman, MD, MSCE is the Chair of the Department of Biostatistics, Epidemiology and Informatics (DBEI), the George S. Pepper Professor of Public Health and Preventive Medicine, a Professor of Epidemiology and Medicine (Renal Electrolyte and Hypertension Division), and the Director of the Center for Clinical Epidemiology and Biostatistics (CCEB). Dr. Feldman earned his MD in 1982 from Boston University before completing a residency in Internal Medicine at the University of California, Los Angeles. He subsequently completed his fellowship training in nephrology at the University of Pennsylvania where he also trained in Clinical Epidemiology. His work has also been recognized through membership in the American Society of Clinical Investigation, the Association of American Physicians, and the American Epidemiological Society. He is Past-President of the American College of Epidemiology. Dr. Feldman is also currently the Editor-in-Chief of the American Journal of Kidney Diseases after serving as past inaugural Deputy Editor of the Clinical Journal of the American Society of Nephrology and past Associate Editor of the Annals of Internal Medicine. Among his numerous national leadership roles, Dr. Feldman leads NIH’s Chronic Renal Insufficiency Cohort Study (CRIC), the major national research effort making fundamental insights into the epidemiology, management, and outcomes of chronic kidney disease. Under his leadership, the CRIC Study has discovered numerous findings with great promise to advance the development of novel therapies to reduce morbidity in this population worldwide. Dr. Feldman also leads NIDDK’s Coordinating Center of its Chronic Kidney Disease Biomarkers Consortium. He is also the director of multiple NIH-funded institutional training grants in the clinical epidemiology of kidney disease, cancer, and neurological disorders. Dr. Feldman’s published scholarship of more than 200 research publications has appeared in many leading biomedical journals.
Rebholz CM, Grams ME, Coresh J, Selvin E, Inker LA, Levey AS, Kimmel PL, Vasan RS, Eckfeldt JH, Feldman HI, Hsu C, Lutsey PL, Chronic Kidney Disease Biomarkers Consortium: Serum fibroblast growth factor-23 is associated with incident kidney disease. Journal of the American Society of Nephrology 26(1): 192-200, 2015.
Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER III, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI and the CRIC Study Investigators: Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Annals Internal Medicine 162(4): 258-65, 2015.
Wilson FP, Shashaty M, Testani J, Aqeel I, Borovskiy Y, Ellenberg SS, Feldman HI, Fernandez H, Gitelman Y, Lin J, Negoianu D, Parikh CR, Reese PP, Urbani R, Fuchs B: Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomized controlled trial. Lancet 385(9981): 1966-74, 2015.
Reese PP, Bloom RD, Feldman HI, Garg AX, Mussell A, Shults J, Silber JH: Selecting appropriate controls for kidney donors-reply. American Journal of Transplantation 15(1): 287-88, 2015.
Fufaa GD1, Weil EJ, Nelson RG, Hanson RL, Bonventre JV, Sabbisetti V, Waikar SS, Mifflin TE, Zhang X, Xie D, Hsu CY, Feldman HI, Coresh J, Vasan RS, Kimmel PL, Liu KD, for the Chronic Kidney Disease Biomarkers Consortium Investigators: Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 58(1): 188-98, 2015.